All Drug Discovery articles
-
NewsNRF2 helps cancer cells neutralise formaldehyde while evading cell death
A study led by the Josep Carreras Leukaemia Research Institute has uncovered how cancer cells manage formaldehyde toxicity without compromising their defences against ferroptosis.
-
ArticleHow dormant cancer cells protect pancreatic tumours from CAR T therapy
Researchers have discovered how dormant pancreatic cancer cells manipulate their surroundings to evade CAR T-cell therapy, identifying a potential therapeutic target for overcoming treatment resistance.
-
NewsBlood-thinning drug shows promise against osteoarthritis inflammation
Researchers have identified dabigatran, an approved anticoagulant, as a candidate for treating osteoarthritis after screening FDA-approved drugs for compounds capable of simultaneously suppressing two key inflammatory mediators.
-
NewsEnzyme structure mapped as new drug target for rare brain disorder
Scientists at the Icahn School of Medicine at Mount Sinai have resolved the complete structure of the AASS enzyme, revealing potential new strategies for treating the rare inherited metabolic disorder glutaric aciduria type 1.
-
ArticleWhat a protein damage score can, and can’t, tell drug developers
Protein damage could provide a valuable readout for evaluating potential anti-ageing therapies, but reducing complex biological responses to a single score raises important questions about interpretation and validation.
-
NewsDALTAC prostate cancer strategy traps cancer proteins to overcome resistance
Researchers at the University of Michigan have developed a bifunctional small molecule approach that traps two prostate cancer-driving proteins in an inactive state.
-
ArticleSearching for Alzheimer’s drug targets, one cell at a time
The PsychAD Consortium is using human genetics, single-cell genomics and automated screening to pinpoint potential drug targets for Alzheimer’s disease and investigate their therapeutic potential.
-
NewsRCF awards $1m to advance tau-targeting drug discovery
The Rainwater Charitable Foundation has awarded more than $1m through its Sprint to Lead programme to support three one-year projects targeting tau protein in primary tauopathies, including PSP, CBD and FTD.
-
NewsAlzheimer’s risk gene CASS4 found to regulate microglial immune response
Researchers at the University of Virginia Health have uncovered a previously unknown role for the Alzheimer’s risk gene CASS4 in controlling microglial activity, suggesting that restoring its function could offer a novel strategy for slowing disease progression.
-
ArticleWhy better technology does not always lead to better R&D decisions
Making better decisions in drug discovery is not down to implementing more tools. Here, Dr Harsh Shah reveals why teams must start by defining the scientific question.
-
NewsDNA enhancer switch drives androgen receptor breast cancer suppression
A small regulatory DNA element called HRRINT3 has been found to play a critical role in enabling the androgen receptor to suppress cell growth in oestrogen receptor-positive breast cancer, pointing towards new therapeutic strategies for patients with advanced disease.
-
Company profileLight-powered reaction converts sulfonamides into drug discovery building blocks
A light-driven chemical reaction developed at Florida State University can strip sulfur atoms from sulfonamides to produce anilines, offering a new route to repurpose previously intractable compounds for drug discovery.
-
ArticleHow asymmetric binding affinity enables reversible IL-12 switches
Stronger binding isn’t always better. Dr Teresa Barata of FairJourney Bio explains how researchers engineered a dual-specificity antibody switch designed to control IL-12 activity in tumours.
-
NewsFramework proposed to advance plant-derived anti-inflammatory drug discovery
A review led by researchers at the Naval Medical University proposes a structured framework for evaluating plant-derived anti-inflammatory compounds, warning that pathway inhibition alone is insufficient evidence of direct molecular target engagement.
-
ArticleWhat tissue accumulation can reveal about oligonucleotide safety
Oligonucleotides can remain in tissues long after disappearing from circulation, but does accumulation necessarily indicate toxicity? Dr Tina Rogers examines the evidence needed to interpret preclinical safety findings.
-
NewsZinc finger protein found to suppress amyloid-beta aggregation in Alzheimer’s
A protein best known for regulating genes has been shown to suppress amyloid-beta aggregation and reduce aggregate toxicity in a transgenic mouse model of Alzheimer’s disease.
-
NewsTriptolide plant compound could improve response to epigenetic cancer drugs
Researchers at Johns Hopkins have identified a natural plant compound capable of blocking an enzyme that degrades DNA methyltransferase inhibitors, offering a potential strategy to overcome resistance to epigenetic cancer therapies.
-
ArticleStrong binding isn’t enough – why cellular target engagement matters
Promising compounds don’t always engage their targets in living cells. At ELRIG Drug Discovery 2026, Dr Joshua Sopp of Promega discusses why earlier cellular testing matters and how BRETSA could help researchers investigate new drug targets.
-
ReportLab Automation 2026: Inside the labs making drug discovery faster and more reliable
Six scientists and industry experts discuss the challenges of automating drug discovery, from improving screening reliability and reproducibility to developing more autonomous laboratories.
-
NewsNovel RNA-protein interactions reveal conserved SARS-CoV-2 antiviral targets
A new study has mapped previously unknown RNA-protein interactions across the SARS-CoV-2 genome, identifying conserved sites involving RdRp and the nucleocapsid protein as potential antiviral drug targets less susceptible to mutational escape.


